Compare GeneDx Holdings Corp (WGS) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GeneDx Holdings Corp vs Block Inc — how do they compare? GeneDx Holdings Corp trades at $67.29 (market cap $2.02B), while Block Inc trades at $77.24 (market cap $45.20B). The key difference: Block Inc is far larger — about 22.4× GeneDx Holdings Corp's market cap, and Block Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GeneDx Holdings Corp for 19 Days and Block Inc for 78 Days on average.
| WGS | XYZ | |
|---|---|---|
Market Cap | $2.02B | $45.20B |
Volume | 734,640 | 8,386,094 |
Sector | Health | Technology |
52-Week High | $167.51 | $84.85 |
52-Week Low | $34.51 | $49.04 |
Typical Hold Time | 19 Days | 78 Days |
Enterprise Value | $2.05B | $40.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Block (XYZ) trades at $77.24, up 1.54% today, with strong analyst support (77% buy ratings) and a $97.47 consensus price target suggesting 26% upside. Recent quarters show earnings momentum with Q1 and Q2 2026 beats, though Q3 2026 results are pending. Revenue growth has been steady, reaching $24.19B in 2025, but net margins remain thin at 1.43%. Technical indicators are bearish overall, with the stock testing resistance near $77.
The stock offers growth potential from expanding Square and Cash App ecosystems and new banking initiatives, but faces risks from high P/E valuation (134.34), competitive pressures, and insider selling. Positive earnings surprises and institutional accumulation provide support, though profitability consistency and debt levels warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
